Yassir Sirajeldin, MD
Nephrology · Southfield, MINPI 1306111463
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.1%), speaking fees and education — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Aurinia Pharma U.S., Inc. at 48.2% of the total. Among nephrology clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 404 payments — averaging $50.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aurinia Pharma U.S., Inc.$10K
- AstraZeneca$2K
- Bayer$1K
- Otsuka America Pharmaceutical, Inc.$782
- Vifor Pharma, Inc.$770
- Boehringer Ingelheim$664
- plus $5K from 26 others
What the payments were for
- Speaking & faculty fees$8,75043%
- Travel & lodging$250%
- Food & beverage$11,13055%
- Education$3042%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aurinia Pharma U.S., Inc. | 31 | $9,741 |
| AstraZeneca(2 entities) | 62 | $2,203 |
| Bayer | 40 | $1,056 |
| Otsuka America Pharmaceutical, Inc. | 20 | $782 |
| Vifor Pharma, Inc. | 39 | $770 |
| Boehringer Ingelheim | 25 | $664 |
| Amgen(2 entities) | 26 | $630 |
| GSK | 21 | $598 |
| Ardelyx, Inc. | 10 | $483 |
| Travere Therapeutics, Inc. | 22 | $357 |
| Mallinckrodt Hospital Products Inc. | 11 | $312 |
| ANI Pharmaceuticals, Inc. | 14 | $298 |
| Calliditas Therapeutics US Inc. | 14 | $287 |
| Fresenius USA Marketing, Inc. | 15 | $258 |
| Novo Nordisk | 3 | $252 |
| Akebia Therapeutics Inc | 11 | $214 |
| Novartis | 8 | $195 |
| OPKO Pharmaceuticals, LLC | 10 | $186 |
| Medtronic(2 entities) | 2 | $131 |
| Baxter Healthcare | 2 | $127 |
| Recor Medical Inc | 1 | $125 |
| Ablative Solutions, Inc. | 1 | $121 |
| Johnson & Johnson | 1 | $84 |
| Xeris Pharmaceuticals, Inc. | 4 | $81 |
| Sanofi | 2 | $58 |
| Mallinckrodt Enterprises LLC | 2 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
| Alnylam Pharmaceuticals Inc. | 1 | $27 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Apellis Pharmaceuticals, Inc. | 1 | $22 |
| Shield Therapeutics Inc | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LUPKYNIS$9,367
- FARXIGA$760
- XPHOZAH 30 MG$375
- Kerendia$247
- BENLYSTA$247
- JARDIANCE$243
- JYNARQUE$213
- PARADISE RENAL DENERVATION SYSTEM$125
- LOKELMA$125
- Tavneos$120
- SYMPLICITY G3$118
- Wegovy$118
- ACTHAR$109
- Renal - PD$102
How this compares
$20,209 in reported general payments places this provider in the 90th percentile of 325 nephrology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 214 | $172,816 |
| Tolvaptan | 12 | $51,376 |
| VelphoroSucroferric Oxyhydroxide | 20 | $42,464 |
| LokelmaSodium Zirconium Cyclosilicate | 39 | $41,515 |
| JardianceEmpagliflozin | 32 | $33,330 |
| KerendiaFinerenone | 32 | $30,054 |
| OzempicSemaglutide | 24 | $27,414 |
| Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med | 177 | $11,467 |
| Calcium Acetate | 54 | $6,193 |
| Cinacalcet Hcl | 20 | $3,649 |
| Amlodipine-ValsartanAmlodipine Besylate/Valsartan | 30 | $2,567 |
| Carvedilol | 179 | $2,393 |
| Amlodipine Besylate-BenazeprilAmlodipine Besylate/Benazepril | 53 | $1,908 |
| Midodrine Hcl | 24 | $1,878 |
| Torsemide | 106 | $1,825 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $2,203 | $214,331253 claims |
| Fresenius USA Marketing, Inc.Velphoro | $258 | $42,46420 claims |
| Boehringer IngelheimJardiance | $664 | $33,33032 claims |
| BayerKerendia | $1,056 | $30,05432 claims |
| Novo NordiskOzempic | $252 | $27,41424 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 325 nephrology providers in Michigan.
Other nephrology in Southfield
- Fawaz Al-EjelSouthfield$8K
- Iram RehmanSouthfield$7K
- Yousef BaderSouthfield$7K
- Valerie DyeSouthfield$5K
- Alexander YevzlinAnn Arbor$1.1M
- Muwaffaq SalamehBay City$164K
- Laura MarianiAnn Arbor$150K
- Crystal Gardner-MartinLivonia$140K
- Katherine KwonSaint Joseph$111K
- Anatole BesarabDetroit$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.